These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 19635672

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.
    Gutiérrez-de-Terán H, Nervall M, Ersmark K, Liu P, Janka LK, Dunn B, Hallberg A, Aqvist J.
    Biochemistry; 2006 Sep 05; 45(35):10529-41. PubMed ID: 16939205
    [Abstract] [Full Text] [Related]

  • 4. The potential of P1 site alterations in peptidomimetic protease inhibitors as suggested by virtual screening and explored by the use of C-C-coupling reagents.
    Weik S, Luksch T, Evers A, Böttcher J, Sotriffer CA, Hasilik A, Löffler HG, Klebe G, Rademann J.
    ChemMedChem; 2006 Apr 05; 1(4):445-57. PubMed ID: 16892380
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.
    Nöteberg D, Hamelink E, Hultén J, Wahlgren M, Vrang L, Samuelsson B, Hallberg A.
    J Med Chem; 2003 Feb 27; 46(5):734-46. PubMed ID: 12593654
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
    Hidaka K, Kimura T, Tsuchiya Y, Kamiya M, Ruben AJ, Freire E, Hayashi Y, Kiso Y.
    Bioorg Med Chem Lett; 2007 Jun 01; 17(11):3048-52. PubMed ID: 17400453
    [Abstract] [Full Text] [Related]

  • 9. New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates.
    Fäh C, Hardegger LA, Baitsch L, Schweizer WB, Meyer S, Bur D, Diederich F.
    Org Biomol Chem; 2009 Oct 07; 7(19):3947-57. PubMed ID: 19763297
    [Abstract] [Full Text] [Related]

  • 10. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Abdel-Rahman HM, Kimura T, Hidaka K, Kiso A, Nezami A, Freire E, Hayashi Y, Kiso Y.
    Biol Chem; 2004 Nov 07; 385(11):1035-9. PubMed ID: 15576323
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
    Ersmark K, Feierberg I, Bjelic S, Hamelink E, Hackett F, Blackman MJ, Hultén J, Samuelsson B, Aqvist J, Hallberg A.
    J Med Chem; 2004 Jan 01; 47(1):110-22. PubMed ID: 14695825
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
    Dali B, Keita M, Megnassan E, Frecer V, Miertus S.
    Chem Biol Drug Des; 2012 Apr 01; 79(4):411-30. PubMed ID: 22129033
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.